Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic myeloid leukemia
Pharma
Novartis' Scemblix leaps into newly diagnosed CML
The first-line nod marks an important step for the Gleevec follow-up on its way toward achieving the company's peak sales estimate of $3 billion.
Angus Liu
Oct 29, 2024 3:56pm
MediLink, Takeda, Ascentage and China NMPA—Fierce Pharma Asia
Jun 21, 2024 8:23am
Takeda circles Ascentage's Scemblix challenger for up to $1.3B
Jun 14, 2024 11:30am
ASCO: Novartis' Scemblix proves benefits over Gleevec in CML
May 31, 2024 8:00am
Novartis’ ASCO booth uses AR to simulate patient burden
May 29, 2024 2:46pm
After rejection, FDA accepts Xspray's leukemia med resubmission
Feb 12, 2024 10:33am